IMBiologics

IMBiologics Corp. is a biotechnology company that develops immunomodulatory antibody therapeutics for autoimmune diseases and cancer. It uses its Optimal Antibody Modality Manufacturing Technology (IM-OpDECon) to create differentiated treatments in autoimmune disease and immuno-oncology based on immuno-modulatory biologics. Its products include IMB-101, a bispecific antibody targeting OX40L and TNF to modulate Th1/Th17-mediated pathological immune responses; IMB-102; IMB-201, an antibody-drug conjugate targeting the tumor-specific antigen HLA-G; and IMB-402, a bispecific anticancer vaccine antibody that uses the ePENDY (IgM-Agonist) modality to activate cancer cell-specific T cells. Founded in 2020, the company is based in Suwon-si, South Korea.